NANOPHARMACEUTICALS LLC has a total of 31 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2004. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, machines and biotechnology are VALCURIA AB, KANGMEI BAONING SICHUAN PHARMACEUTICAL CO LTD and Guizhou shenqi pharmaceutical co ltd.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | EPO (European Patent Office) | 7 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Australia | 2 | |
#5 | Canada | 2 | |
#6 | China | 2 | |
#7 | Brazil | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Machines | |
#3 | Biotechnology | |
#4 | Measurement | |
#5 | Micro-structure and nano-technology | |
#6 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Unspecified technologies | |
#4 | Analysing materials | |
#5 | Nanostructure applications | |
#6 | Unspecified technologies | |
#7 | Peptides | |
#8 | Microorganisms | |
#9 | Heterocyclic compounds | |
#10 | Microbiology |
# | Name | Total Patents |
---|---|---|
#1 | Mousa Shaker A | 19 |
#2 | Rajabi Mehdi | 17 |
#3 | Davis Paul J | 12 |
#4 | Mousa Shaker | 11 |
#5 | Karakus Ozlem O | 10 |
#6 | Davis Faith B | 5 |
#7 | Davis Paul | 1 |
#8 | Glinsky Gennadi V | 1 |
#9 | Drusano George | 1 |
#10 | Hay Bruce A | 1 |
Publication | Filing date | Title |
---|---|---|
US10961204B1 | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors | |
US10328043B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | |
CA3026504A1 | Non-cleavable polymer conjugated with .alpha..nu..beta.3 integrin thyroid antagonists | |
US2017080058A1 | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders | |
WO2015074050A1 | Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof | |
US2014294931A1 | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders | |
EP1793814A2 | Thyroid hormone analogs for inhibiting angiogenesis | |
EP2335694A1 | Thyroid hormone analogs and methods of use |